Wells Fargo & Co Reiterates Sell Rating for Teva Pharmaceutical Industries (TEVA)

Teva Pharmaceutical Industries (NYSE:TEVA)‘s stock had its “sell” rating reaffirmed by research analysts at Wells Fargo & Co in a report issued on Monday.

Other equities analysts have also recently issued research reports about the company. Piper Jaffray Companies set a $16.00 price objective on Teva Pharmaceutical Industries and gave the company a “hold” rating in a report on Thursday, December 14th. Cantor Fitzgerald set a $18.00 price objective on Teva Pharmaceutical Industries and gave the company a “hold” rating in a report on Wednesday, January 3rd. Royal Bank of Canada boosted their price objective on Teva Pharmaceutical Industries from $8.00 to $13.00 and gave the company an “underperform” rating in a report on Sunday, November 5th. Leerink Swann initiated coverage on Teva Pharmaceutical Industries in a report on Tuesday, January 2nd. They issued an “underperform” rating and a $15.00 price objective for the company. Finally, ValuEngine raised Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a report on Thursday, January 11th. Eight investment analysts have rated the stock with a sell rating, sixteen have issued a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $21.32.

Teva Pharmaceutical Industries (NYSE:TEVA) traded up $0.32 during trading on Monday, hitting $21.02. The stock had a trading volume of 20,750,000 shares, compared to its average volume of 27,110,000. The company has a debt-to-equity ratio of 1.20, a current ratio of 0.96 and a quick ratio of 0.66. The firm has a market cap of $20,960.00, a PE ratio of -3.58, a price-to-earnings-growth ratio of 1.48 and a beta of 0.54. Teva Pharmaceutical Industries has a 52-week low of $10.85 and a 52-week high of $37.94.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings results on Thursday, November 2nd. The company reported $0.95 EPS for the quarter, missing the Zacks’ consensus estimate of $1.03 by ($0.08). Teva Pharmaceutical Industries had a positive return on equity of 15.70% and a negative net margin of 24.35%. equities research analysts forecast that Teva Pharmaceutical Industries will post 3.74 EPS for the current year.

A number of large investors have recently bought and sold shares of TEVA. San Francisco Sentry Investment Group CA acquired a new position in shares of Teva Pharmaceutical Industries during the 2nd quarter worth approximately $106,000. Penserra Capital Management LLC acquired a new position in shares of Teva Pharmaceutical Industries during the 3rd quarter worth approximately $129,000. Fieldpoint Private Securities LLC acquired a new position in shares of Teva Pharmaceutical Industries during the 3rd quarter worth approximately $171,000. Chevy Chase Trust Holdings Inc. boosted its holdings in shares of Teva Pharmaceutical Industries by 81.5% during the 3rd quarter. Chevy Chase Trust Holdings Inc. now owns 12,239 shares of the company’s stock worth $215,000 after purchasing an additional 5,497 shares during the last quarter. Finally, Bank of Nova Scotia boosted its holdings in shares of Teva Pharmaceutical Industries by 8.3% during the 2nd quarter. Bank of Nova Scotia now owns 6,903 shares of the company’s stock worth $229,000 after purchasing an additional 528 shares during the last quarter. Institutional investors own 51.89% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Wells Fargo & Co Reiterates Sell Rating for Teva Pharmaceutical Industries (TEVA)” was originally published by American Banking News and is owned by of American Banking News. If you are accessing this article on another domain, it was stolen and republished in violation of US & international copyright law. The correct version of this article can be viewed at https://www.americanbankingnews.com/2018/01/22/wells-fargo-co-reiterates-sell-rating-for-teva-pharmaceutical-industries-teva.html.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply